Partnering
The Opportunity
Neurodegenerative diseases represent one of the largest and most urgent unmet medical needs worldwide. Despite decades of research and substantial investment, current treatment options remain limited.
The field faces important gaps like:
- Limited disease-modifying oral treatments suitable for long-term use
- Inefficient penetration of the blood-brain barrier and transmembrane transfer to reach intracellular targets
- Safety and tolerability challenges, particularly in elderly, polymedicated patient populations
A central challenge across these diseases is pathological protein aggregation, a well-validated biological driver of neurodegeneration. While many therapeutic strategies have focused on downstream manifestations such as plaques, growing evidence points to soluble, toxic oligomers as the key disease-driving species that spread within and between cells, disrupt neuronal function, and accelerate disease progression.
These challenges define a clear opportunity for a differentiated approach capable of addressing the underlying biology of neurodegeneration more directly and broadly.
Why Priavoid?
Priavoid offers a distinct and broadly applicable approach based on a novel, multi-disease platform designed to inhibit and reverse disease-specific protein aggregation, targeting the underlying cause of neurodegeneration.
At the core of Priavoid’s strategy is a new class of orally available all-d-peptide detanglers that directly target toxic oligomer species, rather than relying on immune-mediated clearance or plaque removal.
Priavoid’s compounds are engineered to:
- Efficiently reach the site of action, including both the brain and the intracellular space, without the need for an additional carrier system
- Detangle and disassemble toxic oligomers into non-toxic monomers
- Act independently of protein conformation or strain
- Avoid immune activation, supporting a favorable safety profile for long-term use and potential combination treatments
Our differentiated mechanism of action enables us to pursue disease-modifying treatments across multiple neurodegenerative indications using a single, scalable platform. Our goal is to translate our detangler platform into treatments that deliver meaningful clinical benefit for patients, while creating flexible and value-driven collaboration pathways for key partners.
Our Existing Partners
Priavoid has an extensive network that includes academic partners like the Forschungszentrum Jülich (FZJ) and the Heinrich-Heine-University (HHU), with a strong research focus on neurodegenerative disorders, particularly Alzheimer’s and Parkinson’s disease.
Priavoid has an extensive network that includes academic partners like the Forschungszentrum Jülich (FZJ) and the Heinrich-Heine-University (HHU), with a strong research focus on neurodegenerative disorders, particularly Alzheimer’s and Parkinson’s disease.
Forschungszentrum Jülich and Heinrich-Heine-University are the scientific origins of Priavoid. The Institute of Physical Biology (HHU) is led by Prof. Dr. Dieter Willbold, Priavoid’s CSO and co-founder, who also served for 20 years as Director of the Institute of Structural Biochemistry (IBI-7) at Forschungszentrum Jülich. All parties benefit from close scientific exchange and collaboration in specific research areas.
Our Institutional Partners
Priavoid is supported by strong regional governmental and entrepreneurial institutions, as well as renowned international foundations dedicated to advancing therapeutic innovations in neurodegenerative diseases.
PRinnovation GmbH, a subsidiary of the Federal Agency for Disruptive Innovation (SPRIN-D), entered into a research collaboration with Priavoid in 2021 to advance the clinical development of our Alzheimer’s program PRI-002.
In addition, Priavoid has received funding from the Michael J. Fox Foundation to support its Parkinson’s disease program PRI-100, as well as a grant from the Alzheimer’s Association and the Rainwater Charitable Foundation for the preclinical development of our tau-targeting program PRI-200. Priavoid has also received funding from the German Federal Ministry of Education and Research (BMBF) through the PRADA project to support the optimization of all-D-peptides.
